Search Bar & Filters
Found 105 Actively Recruiting clinical trials
Actively Recruiting
Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.
Actively Recruiting
Researchers are evaluating the safety and effects of marstacimab, a study medicine, for treating hemophilia in male pediatric patients aged 1 to 17 years. The study focuses on severe Hemophilia A and moderately severe to severe Hemophilia B, including participants with or without inhibitors. Enrollment is done sequentially by age groups starting with adolescents, then children aged 6 to 11 years, followed by children aged 1 to 5 years. All participants will receive weekly subcutaneous injections of marstacimab, initially administered at the study site with subsequent doses given either at home or at the study site over a 12-month treatment period. The study compares participants experiences during treatment to their historical bleeding and treatment records to assess how marstacimab may help prevent bleeding episodes common in hemophilia. Participants will be involved for about 14 months, including a screening period of roughly one month, 12 months of treatment, and a one-month follow-up. They will attend at least 10 study visits, with the option of completing two visits at home if regulations allow, and receive six scheduled phone calls approximately every two months. Researchers will monitor bleeding rates, safety events, immune responses, joint health, and quality of life during this time.
Actively Recruiting
Researchers are studying chronic Philadelphia-negative myeloproliferative syndromes, which are blood disorders including essential thrombocythemia, polycythemia vera, and myelofibrosis. Myelofibrosis may occur initially or develop from the other conditions and is marked by scar-like tissue in the bone marrow, indicating a more severe disease stage. Currently, bone marrow biopsy is the only way to assess this fibrosis, and the study aims to find less invasive methods by tracking cells expressing the CCR2 receptor, a marker of fibrosis. The study evaluates a new diagnostic approach using flow cytometry on blood samples to identify CCR2-positive cells and PET-CT imaging with a targeted tracer called 68Ga-DOTA-ECL1i that binds to these cells. This approach is being tested both in preclinical models and in patients with myeloproliferative neoplasms. The project includes tracking these cells for diagnosis, functional imaging in mice, and imaging in human participants to support diagnosis and monitoring. Participants will have their blood tested for CCR2 expression on certain cells and undergo PET-CT imaging sessions using the tracer. Researchers will measure the percentage of circulating CD34CCR2 cells as the main outcome and assess bone marrow activity and tracer uptake in other sites during imaging. The study supports diagnosis and disease monitoring without invasive biopsies and includes follow-up assessments to understand fibrotic progression. Participation involves blood tests and imaging, with evaluations done at enrollment and imaging sessions.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are conducting a Phase 3 pediatric clinical trial to study chronic weight management in children and adolescents aged 6 to 17 years who have obesity or are overweight with related health conditions. The study aims to create a master framework that evaluates the safety and effectiveness of medications for these participants. This trial is part of a broader platform trial design with multiple intervention sub-studies ISAs that may start independently as treatments become available. Participants will receive either the study drug orforglipron or a placebo orally, with each intervention sub-study detailing specific treatments. The master protocol sets common entry criteria for all participants across the different sub-studies. Results from the trial will be reported when all intervention sub-studies are completed. During the trial, participants will be monitored from baseline through 72 weeks, with assessments of how many are allocated to each intervention sub-study. Safety and efficacy will be evaluated through ongoing observation and data collection throughout the study period. The trial spans from screening through long-term follow-up, ensuring comprehensive evaluation of the treatments over time.
Actively Recruiting
Researchers are investigating how plant-based diets affect the gut microbiome and related metabolites in patients with smoldering multiple myeloma sMM. The study aims to show that diets rich in fiber can promote beneficial gut bacteria that produce short-chain fatty acids SCFAs, potentially preventing progression to multiple myeloma. This national, multicenter study involves up to 62 sMM patients and focuses on the impact of dietary changes on gut health and immune balance. Participants will be encouraged to follow a balanced, high-fiber diet for 12 weeks, choosing from various diet plans based on their preferences. Medical visits will take place at enrollment and at week 12, with nutritional counseling provided initially, at one month, and as needed. Stool and blood samples will be collected before the diet starts, and again at 4 and 12 weeks to monitor changes in the gut microbiome and SCFA levels. Dietary adherence will be tracked daily through questionnaires and food diaries. During the study, participants will have routine medical visits and sample collections aligned with standard sMM follow-up care. Researchers will compare biological data from baseline and follow-up samples to assess diet effects on SCFA concentration and gut microbiome composition. Evaluation of diet adherence and safety monitoring will also be ongoing throughout the trial, lasting 12 weeks with encouragement to continue plant-based eating beyond this period.
Actively Recruiting
Researchers are conducting a prospective observational study to better understand early-onset gastrointestinal EoGI cancer by examining clinical and demographic data, tumor characteristics, and patient lifestyle habits. The study aims to capture a comprehensive picture of this type of cancer in newly diagnosed patients aged 18 to 49 years. This research is carried out across multiple centers in northern Italy, involving diverse hospital settings. Participants include newly diagnosed EoGI cancer patients confirmed by histology, covering colorectal, gastroesophageal, and pancreatic tumors at any disease stage. The study does not alter any cancer treatments patients receive, which continue as per best clinical practice. Researchers focus on collecting detailed patient data without influencing treatment decisions. During the study, participants provide information on their medical history and lifestyle, which researchers use to characterize the cancer features and patient habits. Follow-up assessments occur at six months, one year, and two years to monitor outcomes. The primary outcome is measured one year from enrollment. The total participation duration extends up to two years, with no additional treatment provided by the study.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
1-10 of 105
1